Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Solid Biosciences Inc. SLDB

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
2.68
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 1 4 3 20 — — — — — — —
Insider Ownership
39.11%

Capital & Financial Ratios

Market Cap
951.09
Revenue
11.25
Net Income
(207.10)
Free Cash Flow
(187.72)
Net Debt
(378.32)
Current Ratio
13.82
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
113.82
P/B ratio
3.42
Past 5Y EPS Growth
41.25%
This Y EPS Growth
11.52%
Next Y EPS Growth
1.62%
Next 5Y EPS Growth
14.00%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 123.64 148.92 189.07 378.32
Receivables — — — —
Inventory — — — —
Other — — — —
129.73 157.30 205.46 395.11
2023 2024 2025 Q'26
Payables 2.03 4.24 3.22 4.36
ST’ Debt — — — —
Other 0.02 3.15 9.20 4.20
14.52 30.26 33.47 28.58
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’22 1.93 6.17 — 0.00
8.09
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (47.23) (52.59) — —
—
’25 (31.85) (37.41) (33.47) (53.55)
(156.29)
’24 (25.19) (21.47) (23.71) (29.64)
(100.01)
’23 (27.99) (27.46) (17.90) (20.82)
(94.18)
’22 (27.19) (15.88) (20.43) (34.48)
(97.98)
’21 (21.37) (17.10) (18.42) (20.87)
(77.76)
’20 (29.27) (13.07) (15.56) 1.31
(56.60)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (47.39) (52.74) — —
—
’25 (31.98) (37.79) (33.56) (54.03)
(157.36)
’24 (25.34) (21.75) (23.72) (29.84)
(100.66)
’23 (28.50) (28.00) (18.28) (20.91)
(95.69)
’22 (27.37) (17.01) (20.67) (35.34)
(100.39)
’21 (21.40) (17.45) (18.66) (21.53)
(79.04)
’20 (29.95) (13.15) (15.64) 1.25
(57.50)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.52) (0.38) — —
—
’25 (0.59) (0.42) (0.48) (0.53)
(1.99)
’24 (0.64) (0.61) (0.79) (1.00)
(3.06)
’23 (1.54) (1.25) (1.05) (1.00)
(4.83)
’22 (3.30) (3.30) (2.71) (0.68)
(10.10)
’21 (2.85) (2.55) (2.40) (2.55)
(10.19)
’20 (8.40) (5.85) (6.60) (4.65)
(25.49)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.21 1.81 3.85 2.41 — — —
Low Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.53 8.20 15.05 7.37 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 87 88 100 121 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.09 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — ‡‡‡‡‡ 8.09 — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% — — — — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (85.98) (96.01) (124.70) (174.32) ‡‡‡‡‡ — —
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (1,062.28%) 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (85.98) (96.01) (124.70) (174.32) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.64 0.17 (1.14) (0.24) — — —
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.95 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (10.10) (4.83) (3.06) (1.99) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.51) (4.74) (2.45) (1.79) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.28) (0.08) (0.02) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.79) (4.81) (2.47) (1.80) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.87 6.36 3.36 2.06 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.51 19.88 40.82 87.51 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — ‡‡‡ 0.00 — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — ‡‡‡‡‡ 4.25 — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — ‡‡‡‡‡ 0.23 — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — ‡‡‡‡‡ (14.37) — — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — ‡‡‡‡‡ 1.61 — — — — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (97.98) (94.18) (100.01) (156.29) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.41) (1.51) (0.65) (1.07) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (100.39) (95.69) (100.66) (157.36) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 197.13 115.22 127.05 171.98 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.27 1.23 — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (209.45) (122.41) (148.92) (189.07) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 211.67 126.48 137.25 180.01 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34.91%) (45.16%) (70.53%) (82.78%) ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (3,007.80%) (1,598.96%) 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (40.96%) (56.79%) (94.57%) (109.90%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Solid Biosciences Inc. (SLDB), a clinical-stage biotech targeting gene therapies for Duchenne muscular dystrophy (DMD), has ridden the sector’s classic boom-or-bust rollercoaster. After a hyped 2018 IPO that saw shares soar on AAV therapy enthusiasm, SLDB suffered a devastating multi-year plunge—down over 95% from peaks—triggered by an FDA clinical hold on SGT-001 following a patient death, trial delays, relentless cash burn, and massive dilution that ballooned shares outstanding 1,741% while slashing book value per share 94%. Today, trading at depressed levels amid a funding crunch, the stock’s fate pivots on its next-gen candidate, SGT-003, now in early clinical dosing with proof-of-concept data eyed for 2025-26.

Financials underscore the peril: cumulative losses exceed $700M, with 2024 net income at -$125M and free cash flow burning -$2.47 per share; revenue flickered briefly to $13.6M in 2021 before vanishing, projected flat at $5.75M through 2027 amid negative double-digit ROA/ROE. Insider activity raises red flags—a token director buy dwarfed by millions in executive sells since late 2025—while the balance sheet strains under eroding equity and a 1-2 year cash runway, demanding further dilution absent milestones.

Yet analysts see ~150% upside (highs to 220%), betting on SGT-003’s potential to disrupt the $5B+ DMD market, akin to past surges like BridgeBio’s, unlocking partnerships and validation post-Sarepta’s Elevidys. In this high-stakes narrative of redemption or requiem, binary trial outcomes could torque distressed valuations skyward—or accelerate the dilution death spiral—for risk-tolerant investors eyeing catalysts amid biotech’s unforgiving grind.

Read full commentary →

Solid Biosciences Inc. (SLDB) Latest News

News by impact score

Fine-tune

6 Aug

3 , 4:08 PM
Solid Biosciences reported second quarter 2026 financial results and provided business updates. Quarterly financial results and business updates typically produce moderate effects on company trajectory and sentiment.

2 Jun

3 PR Newswire, 7:00 AM
Solid Biosciences partners with NanoMosaic under co-marketing agreement to advance gene therapy delivery and analytics. Co-marketing agreement supports gene therapy development at Solid Biosciences.

12 May

3 GlobeNewswire, 4:08 PM
Solid Biosciences Inc. (SLDB) reported first quarter 2026 financial results and provided business updates. Quarterly financial results and business updates affect key financial performance and investor sentiment.

7 May

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. (SLDB) dosed the first participant in the Phase 3 IMPACT DUCHENNE clinical trial evaluating SGT-003, an investigational gene therapy for Duchenne muscular dystrophy (DMD). Initiating dosing in a Phase 3 trial for DMD gene therapy marks a pivotal milestone advancing toward potential approval and market entry.

28 Apr

4 , 8:00 AM
Solid Biosciences Inc. (SLDB) received European Commission Orphan Drug Designation for SGT-003, its investigational gene therapy for Duchenne Muscular Dystrophy, granting benefits like market exclusivity, protocol assistance, and reduced fees to support development. EU Orphan Drug Designation for SGT-003 provides regulatory incentives and market exclusivity, significantly boosting SLDB's gene therapy prospects for DMD and investor confidence.

19 Mar

4 GlobeNewswire, 4:12 PM
Solid Biosciences Inc. (SLDB) reported fourth quarter and full-year 2025 financial results, highlighting business updates on pipeline progress, cash position, and strategic initiatives. Financial results and business updates signal pipeline advancements and financial health, significantly influencing investor sentiment and stock performance.

12 Mar

4 TipRanks, 1:10 PM
Solid Biosciences reports interim results from SGT-003 trial reinforcing confidence in its potential as a Duchenne muscular dystrophy gene therapy. Positive interim data for SGT-003 signals major progress in Solid Biosciences' lead gene therapy program, likely boosting investor sentiment and stock performance.

11 Mar

4 GlobeNewswire, 1:01 PM
Solid Biosciences announced positive interim clinical data from the Phase 1/2 INSPIRE DUCHENNE trial, showing promising safety and efficacy signals in patients with Duchenne muscular dystrophy. Positive interim Phase 1/2 data advances SLDB's lead Duchenne gene therapy candidate, potentially accelerating regulatory progress and enhancing investor confidence.

6 Mar

5 GlobeNewswire, 8:31 AM
Solid Biosciences Inc. (SLDB) announced an oversubscribed $240 million private placement, attracting strong investor interest to fund its gene therapy programs. Oversubscribed $240 million private placement delivers transformative capital infusion for clinical advancement and long-term prospects in gene therapy.

15 Feb

4 www.marketbeat.com, 5:35 AM
Solid Biosciences announces FDA's constructive path forward for SGT-003 DMD gene therapy study and shares early positive updates from Friedreich’s Ataxia program. FDA path for lead SGT-003 DMD candidate and early Friedreich’s Ataxia progress mark significant regulatory and pipeline advancements boosting future prospects.

9 Feb

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. received positive feedback from the FDA following a Type C meeting regarding its SGT-003 gene therapy for Duchenne Muscular Dystrophy. The FDA's input is expected to guide the company's development plans and regulatory strategy for the therapy, which aims to address a significant unmet medical need in this patient population. Positive FDA feedback can significantly influence the development and potential market entry of SGT-003, impacting investor sentiment and the company's future trajectory.

6 Feb

3 GlobeNewswirePharmaceutical TechnologyMT NewswiresMT NewswiresInsider MonkeyInsider MonkeyPharmaceutical TechnologyInsider Monkey, 8:00 AM
Solid Biosciences Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its ongoing commitment to advancing gene therapies for Duchenne muscular dystrophy. The summit will feature discussions on the latest trends and innovations in the biotech sector, providing a platform for Solid Biosciences to showcase its developments and engage with investors and industry leaders. Participation in a prominent biotech summit may enhance visibility and investor interest, but the overall impact on the company's trajectory is expected to be limited.

26 Jan

4 Barrons.com, 2:49 PM
Sarepta Therapeutics reported promising results from a three-year study of its gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD), leading to a significant increase in its stock price. The study demonstrated sustained efficacy and safety, raising hopes for patients and investors alike. This development could enhance Sarepta's competitive position in the biotech sector, particularly in the treatment of DMD. The positive study results for Elevidys could significantly influence investor sentiment and market dynamics for related companies, including Solid Biosciences.

16 Jan

3 Zacks, 9:08 AM
Solid Biosciences Inc. is undergoing restructuring efforts aimed at improving its operational efficiency and financial performance. The company is focusing on streamlining its processes and reallocating resources to enhance its product development pipeline. Investors are closely monitoring these changes, as successful implementation could lead to improved market sentiment and potential growth opportunities. However, challenges remain, and the effectiveness of these strategies will be crucial in determining the company's future trajectory. Restructuring efforts may moderately influence financial performance and product innovation but are not expected to drastically change the company's overall trajectory.

15 Jan

4 www.pharmaceutical-technology.com, 12:58 PM
Solid Biosciences Inc. is focusing on its AAV capsid technology to enhance the effectiveness of its gene therapy programs. The company aims to leverage this innovation to improve patient outcomes and drive future growth. With ongoing clinical trials and strategic partnerships, Solid Biosciences is positioning itself to capitalize on advancements in gene therapy, potentially leading to significant developments in the treatment of genetic disorders. The emphasis on AAV capsid technology could significantly enhance product efficacy and market positioning.

13 Jan

4 GlobeNewswire, 4:15 PM
Solid Biosciences Inc. provided an outlook for 2026, highlighting progress in its neuromuscular and cardiac pipeline, as well as increased access to its next-generation capsid AAV-SLB101. The company emphasized its commitment to advancing treatments for Duchenne muscular dystrophy and other conditions, showcasing momentum in its research and development efforts. The advancements in the neuromuscular and cardiac pipeline, along with expanded access to innovative treatments, are likely to significantly impact the company's future performance and investor sentiment.

12 Jan

4 GlobeNewswire, 4:15 PM
Solid Biosciences Inc. has received FDA Orphan Drug Designation for its SGT-212 dual-route gene therapy aimed at treating Friedreich’s Ataxia, a rare genetic disorder. This designation is intended to facilitate the development of therapies for rare diseases, potentially expediting the approval process and providing certain incentives for the company. The FDA Orphan Drug Designation can significantly enhance the development and commercialization prospects for SGT-212, impacting the company's future performance.

4 GlobeNewswire, 8:05 AM
Solid Biosciences Inc. has initiated the Phase 1b FALCON trial by dosing the first participant with SGT-212, a dual-route gene therapy aimed at treating Friedreich’s Ataxia. This trial represents a significant step in the development of innovative treatments for this rare genetic disorder, potentially offering new hope for patients. The initiation of a clinical trial for a novel gene therapy could significantly impact the company's future and market performance.

6 Jan

3 GlobeNewswireInsider MonkeyMT NewswiresMT NewswiresInsider MonkeyMT NewswiresSimply Wall St.MT Newswires, 8:00 AM
Solid Biosciences Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its commitment to advancing gene therapies for Duchenne muscular dystrophy. The conference is a key event for healthcare companies to showcase their innovations and strategies to investors and industry leaders. Participation in a major healthcare conference can enhance visibility and investor interest, potentially impacting market sentiment.

16 Dec

4 , 4:51 PM
Solid Biosciences Inc. announced that Duchenne Muscular Dystrophy (DMD) has been added to the National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services. This inclusion is expected to enhance early detection and intervention for DMD, potentially benefiting patients and families affected by the condition. The decision underscores the importance of screening for genetic disorders and may lead to increased awareness and support for DMD research and therapies. The addition of DMD to the national screening panel is likely to significantly impact Solid Biosciences' market positioning and investor sentiment regarding its therapies.

15 Dec

4 Insider Monkey, 11:10 PM
Sarepta Therapeutics' Elevidys has raised safety concerns, creating a significant opportunity for Solid Biosciences' SGT-003 in the Duchenne muscular dystrophy market. As Elevidys faces scrutiny, SGT-003 may gain traction among patients and investors looking for safer alternatives. Solid Biosciences is positioned to capitalize on this shift, potentially enhancing its market presence and financial outlook. The safety issues surrounding Elevidys could significantly enhance Solid Biosciences' competitive position and market dynamics in Duchenne therapy.

8 Dec

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. will present its proprietary next-generation capsid AAV-SLB101 and its cardiac gene therapy pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum. This showcase highlights the company's advancements in gene therapy aimed at treating cardiac conditions, emphasizing its commitment to innovation in the cardiovascular space. The presentation of new gene therapy technologies at a prominent forum is likely to significantly influence investor sentiment and the company's strategic direction.

1 Dec

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. has received FDA Rare Pediatric Disease Designation for its gene therapy SGT-212, aimed at treating Friedreich’s Ataxia. This designation is expected to expedite the development and review process for the therapy, which targets a rare genetic disorder affecting children. The designation may enhance the company's prospects in the pediatric market and potentially lead to faster access for patients in need. The FDA designation is likely to significantly impact the development timeline and market positioning of SGT-212.

17 Nov

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. has entered into a licensing agreement with Andelyn Biosciences to utilize its proprietary next-generation capsid AAV-SLB101. This collaboration aims to enhance the development of gene therapies, leveraging Solid's innovative technology to potentially improve treatment outcomes in various genetic disorders. The licensing agreement represents a significant strategic move that could enhance product development and market positioning for Solid Biosciences.

6 Nov

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. has received the Innovation Passport designation under the UK Innovative Licensing and Access Pathway for its investigational gene therapy SGT-003, aimed at treating Duchenne Muscular Dystrophy. This designation is intended to expedite the development and regulatory approval process for innovative therapies, potentially enhancing patient access to new treatments. The Innovation Passport designation is a significant regulatory milestone that could accelerate SGT-003's development and market entry, impacting the company's future performance.

3 Nov

4 GlobeNewswireClinical Trials ArenaMT NewswiresClinical Trials ArenaClinical Trials ArenaMT NewswiresClinical Trials ArenaMT Newswires, 4:05 PM
Solid Biosciences Inc. reported its financial results for the third quarter of 2025, highlighting progress in the INSPIRE DUCHENNE clinical trial. The company provided updates on trial milestones and outlined plans for upcoming regulatory discussions, indicating a focus on advancing its therapeutic development for Duchenne muscular dystrophy. Significant updates on clinical trial progress and regulatory discussions could substantially influence the company's future trajectory and investor sentiment.

24 Oct

3 Simply Wall St., 8:56 AM
Solid Biosciences Inc. is under scrutiny regarding its cash management strategies as it navigates financial challenges and seeks to advance its gene therapy programs. Investors are concerned about the company's ability to allocate resources effectively to ensure long-term growth and sustainability. The focus is on whether Solid can balance its operational needs with strategic investments in research and development, particularly in the context of its ongoing projects and market competition. Cash management strategies will moderately influence the company's financial performance and competitive positioning.

1 Oct

3 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. will present at several upcoming scientific meetings, showcasing its advancements and research in gene therapies for Duchenne muscular dystrophy (DMD). The presentations aim to highlight the company's commitment to innovation and collaboration within the scientific community, potentially attracting interest from investors and stakeholders. Presentations at scientific meetings can enhance visibility and credibility, influencing investor sentiment and market performance.

25 Sep

3 GlobeNewswireMT NewswiresMT NewswiresClinical Trials ArenaMT NewswiresClinical Trials ArenaBenzinga, 8:00 AM
Solid Biosciences Inc. will present at the 2025 Neuromuscular Study Group Annual Scientific Meeting, highlighting its commitment to advancing research in neuromuscular diseases. The presentation aims to showcase the company's latest findings and developments in gene therapy and related treatments, contributing to the broader scientific dialogue in the field. The presentation may enhance visibility and credibility in the neuromuscular research community, potentially influencing future collaborations and funding opportunities.

23 Sep

4 GlobeNewswire, 8:00 AM
Solid Biosciences Inc. has entered into a licensing agreement with Kinea Bio to utilize its proprietary next-generation capsid AAV-SLB101. This collaboration aims to enhance the development of gene therapies, leveraging Kinea Bio's expertise in adeno-associated virus (AAV) technology. The agreement is expected to accelerate the advancement of Solid Biosciences' therapeutic programs. The licensing agreement represents a significant strategic move that could enhance product development and competitive positioning in the gene therapy market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us